What “manufacturing patent” covers for Keytruda in the US
Keytruda (pembrolizumab) is protected by multiple patents in the US, and “manufacturing patents” typically refer to patents that cover how the drug is produced rather than the antibody’s medical use. Those can include patents on specific cell lines, production processes, purification or formulation methods, and related manufacturing controls.
Because the exact “manufacturing” patent depends on which aspect of production is being referenced, you need the specific patent number(s) or the specific product/process claim to identify the right one.
How to find Keytruda’s US manufacturing patents (the practical way)
To identify the manufacturing patents relevant to Keytruda in the US, people typically use one of these sources:
- The FDA’s publication related to Keytruda’s patent listings for the drug in the Orange Book (these list patents tied to the product for regulatory purposes).
- Patent databases (search by the assignee (often the developer/holder), “pembrolizumab,” and terms like “manufacturing,” “process,” “cell line,” “purification,” “formulation”).
If you share either the patent number you have in mind or what source you’re looking at (Orange Book, a lawsuit, a specific label), I can help map it to the manufacturing category and explain what it covers.
How long do Keytruda manufacturing patents last in the US?
In the US, patents generally run for 20 years from the earliest effective US filing date, with possible extensions in some circumstances (for example, patent term adjustments). Exact expiration dates vary by patent and claim set, so you need the specific patent number(s) to calculate or confirm timing.
What happens if a biosimilar tries to use a “different manufacturing” approach
Even if a biosimilar uses a different manufacturing process, it still can be blocked if it infringes claims in the relevant patents. Many disputes focus on whether the proposed manufacturing method falls inside or outside the scope of manufacturing process claims.
Which patents usually matter most for “manufacturing” in biologics disputes
In biologic drug patent litigation, the most contested manufacturing-related issues often include:
- Whether the biosimilar’s process steps fall within claimed process parameters or methods.
- Whether the product produced meets claim-linked attributes tied to process definitions.
- Whether any “platform” or process patents asserted by the reference product holder are still in force.
If you want, I can pinpoint the exact manufacturing patent(s)
Tell me one of the following, and I’ll answer with the specific US patent number(s), their expiry, and what manufacturing step/process they cover:
1) the patent number, or
2) the Orange Book listing name you saw (or the patent(s) listed), or
3) a link or screenshot text from where you found the “manufacturing patent” reference.
Sources
I can’t provide specific patent numbers or expiration dates from the info in your message alone. If you share a patent listing or number, I’ll cite the exact records.